Citius Oncology
CTOR
24 hedge funds and large institutions have $54.1M invested in Citius Oncology in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1,160% more capital inflows, than outflows
Capital inflows: $20.6M | Capital outflows: $1.64M
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
60% more funds holding
Funds holding: 15 → 24 (+9)
20.65% more ownership
Funds ownership: 37.77% → 58.42% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wolverine Asset Management
Chicago,
Illinois
|
+$5.97M |
| 2 |
Periscope Capital
Toronto,
Ontario, Canada
|
+$3.33M |
| 3 |
Karpus Investment Management
Pittsford,
New York
|
+$3.28M |
| 4 |
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$2.53M |
| 5 |
Shaolin Capital Management
Miami,
Florida
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mangrove Partners
Greenwich,
Connecticut
|
-$1.52M |
| 2 |
CVI Holdings
Wilmington,
Delaware
|
-$76.4K |
| 3 |
AQR Arbitrage
Greenwich,
Connecticut
|
-$36K |
CTOR Hedge Fund Activity: Q1 2023 in Review
24 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q1 2023, worth a combined $54.1M — up 58% from $34.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CTOR positions and 1 closed out — a net gain of 9 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $5.97M. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.52M sold.
- 24 institutional investors held Citius Oncology (CTOR) as of Q1 2023, up from 15 in Q4 2022.
- Funds reported $54.1M of Citius Oncology stock for Q1 2023, up 58% quarter-over-quarter.
- 10 funds opened new Citius Oncology positions in Q1 2023 and 1 closed out, a net change of +9 holders.
- The largest Citius Oncology buyer in Q1 2023 was Wolverine Asset Management, an estimated $5.97M added.
- The largest Citius Oncology seller in Q1 2023 was Mangrove Partners, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2023.